Hematology-American Society of Hematology Education Program

Papers
(The H4-Index of Hematology-American Society of Hematology Education Program is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Your chemo is no good here: management of high-risk MCL96
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?90
The varieties of therapeutic experience: navigating treatment options for patients with PNH65
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment61
Mastocytosis demystified50
Anticoagulation at the end of life: whether, when, and how to treat42
On the horizon: upcoming new agents for the management of ITP40
Labor and delivery: DIC, HELLP, preeclampsia40
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?32
Neurological manifestations of MGUS30
Challenges and opportunities in the long-term management of immune-mediated TTP29
Recognizing, defining, and managing CAR-T hematologic toxicities29
Bispecific antibody therapies28
Inpatient recognition and management of HLH28
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient26
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma26
Where do immunotherapies stand in management of acute leukemia in adults?25
New therapies in hemophilia: extend the half-life, mimic, or rebalance?25
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL24
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma24
Has PD-1 blockade changed the standard of care for cHL?24
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL23
New approaches to tackle cytopenic myelofibrosis23
Donor selection, graft engineering, and dosing oh my!23
0.1201000213623